Psoriasis
Conditions
Interventions
Group E:Epidural block combined with stellate ganglion block
Group C:Topical treatment
Sponsors
Ruijin Hospital Luwan Branch, Shanghai JiaoTong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Volunteer to participate in the trial and sign the informed consent form. 2. Commit to comply with the research process and cooperate with the whole process research; 3. 18 to 65 years old, male or female patients; 4. Patients with chronic psoriasis, the duration of disease = 6 months, the skin lesion area = 10% of BSA or PASI score = 12 when enrolled and received first intervention; 5. patients undergone other treatments should be eluted before the experiment, the time is as follows: topical vitamin A or glucocorticoid should be eluted for 2 weeks; systemic oral vitamin A should be eluted for 6 months; phototherapy should be eluted for 2 weeks ; psoralen combined with UVA treatment should be eluted for 4 weeks; oral oral immunosuppressive agents such as methotrexate, cyclophosphamide, cyclosporine should be eluted for 4 weeks; biological agents should be eluted for 8 weeks; 6. If it is a woman in the reproductive period, the female patient must agree to take effective contraceptive measures during the study period and within 2 years after the end of the study; 7. If it is a male in the reproductive period, the male patient must agree to take effective contraceptive measures during the study period and within 3 months after the end of the study.
Exclusion criteria
Exclusion criteria: 1. patients with other skin diseases that may affect the assessment of severity; 2. Patients with severe, progressive or uncontrolled vital organs and systemic diseases, including cardiovascular, liver, lung, kidney, gastrointestinal, endocrine, neuropsychiatric, and malignant tumors; 3. Women of childbearing age have a positive pregnancy test or are pregnant or lactation; 4. Be allergic to drugs; 5, patients with severe coagulopathy, severe thrombocytopenia or patients with hemoglobin 35kg/m2); 11. Other circumstances that the investigator believes are not suitable for the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PASI score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum cytokines;DL-QI scale; | — |
Countries
China
Contacts
Public ContactYu Buwei
Ruijin Hospital Luwan Branch, Shanghai JiaoTong University School of Medicine
Outcome results
None listed